Morgan Stanley raised their stock price forecast on Berkeley Lights to $80 from $65, assigning an “Equal-weight” rating and said the leading digital cell biology company’s top-line earnings beat in its first quarter was driven by robust system installs to cell therapy and CRO/CDMO customers and a strong recovery in recurring revenue of the expanding installed base.
On Thursday, Berkeley Lights reported total revenue of $18.2 million for the third quarter, representing a 16% increase over the same period in 2019 and a 72% increase compared to the second quarter of 2020. That was higher than the Wall Street estimate of $15.3 million.
Berkeley Lights’ shares closed 4.59% higher at $95.00 on Friday; the stock is up over 85% since it began trading on the Nasdaq Global Select Market on July 17, 2020.
For more information please refer to the original article: https://www.fxempire.com/forec...
已编辑 16 Nov 2020, 10:14
风险提示：本文所述仅代表作者个人观点，不代表 Followme 的官方立场。Followme 不对内容的准确性、完整性或可靠性作出任何保证，对于基于该内容所采取的任何行为，不承担任何责任，除非另有书面明确说明。
暂无评论，立马抢沙发